Protocols

Orum takes $8M in Series A; Twist bags $27M in venture financing

Daejeon, Korea-based Orum Therapeutics closed its Series A funding with $8 million from InterVest, KB Investment (KBIC)/Solidus Investment, and LB Investment. “We were impressed with Orum’s cell-penetrating antibody platform, which can transform antibodies to effectively target undruggable cytosolic targets, without chemical conjugation and with target cell specificity,” said Yeo Jung Moon, investment division director at Intervest.

→ San-Francisco-based Twist Biosciences, which specializes in high-quality DNA synthesis, raised an additional $27 million in venture financing, bringing its total raised up to $191 million. The funding includes a key investment from Biomatics Capital along with new investors Reinet Fund S.C.A., F.I.S., NFT Investment Limited, KANGMEI Group, Bay City Capital GF Xinde LifeScience Investment Fund, 3W Partners Capital and Ditch Plains Capital Management LP.

JSR Corporation acquired Selexis SA; the terms of the agreement were not disclosed. JSR plans to integrate Selexis with KBI bio, which they purchased in 2015.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

PODD 2017

BioNJ CEO Summit 2017